Needham & Company LLC reissued their buy rating on shares of I-Mab (NASDAQ:IMAB - Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $5.00 price target on the stock.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of I-Mab in a research report on Wednesday.
Check Out Our Latest Stock Analysis on I-Mab
I-Mab Stock Performance
Shares of IMAB stock traded down $0.26 during trading hours on Wednesday, hitting $2.05. 392,373 shares of the company were exchanged, compared to its average volume of 395,220. I-Mab has a one year low of $0.60 and a one year high of $3.08. The business's 50-day simple moving average is $1.75 and its two-hundred day simple moving average is $1.20.
Hedge Funds Weigh In On I-Mab
A number of hedge funds have recently added to or reduced their stakes in IMAB. HBK Sorce Advisory LLC bought a new position in shares of I-Mab during the first quarter valued at approximately $38,000. Ground Swell Capital LLC acquired a new stake in shares of I-Mab in the 1st quarter worth about $53,000. Millennium Management LLC increased its holdings in shares of I-Mab by 763.1% in the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after acquiring an additional 86,424 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of I-Mab in the 4th quarter worth about $93,000. Finally, Cantor Fitzgerald L. P. acquired a new stake in shares of I-Mab in the 4th quarter worth about $119,000. Institutional investors and hedge funds own 38.38% of the company's stock.
About I-Mab
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Featured Stories
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.